News &

Press

venBio news

“venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies.”

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

Apr 20, 2023

Abdera skyrockets out of stealth with $142M as radiopharmaceutical ambitions take flight

Apr 20, 2023

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Feb 27, 2023

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

Feb 27, 2023

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

Feb 26, 2023

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Feb 24, 2023

Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

Feb 22, 2023

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2024 venBio. All Rights Reserved.